Cargando…

Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT

Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcone, Colomba, Buzzi, Maria Paola, Bozzini, Sara, Boiocchi, Chiara, D'Angelo, Angela, Schirinzi, Sandra, Esposito, Ciro, Torreggiani, Massimo, Choi, Jasmine, Ochan Kilama, Michael, Mancia, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306936/
https://www.ncbi.nlm.nih.gov/pubmed/22474401
http://dx.doi.org/10.1155/2012/874149
_version_ 1782227257451872256
author Falcone, Colomba
Buzzi, Maria Paola
Bozzini, Sara
Boiocchi, Chiara
D'Angelo, Angela
Schirinzi, Sandra
Esposito, Ciro
Torreggiani, Massimo
Choi, Jasmine
Ochan Kilama, Michael
Mancia, Giuseppe
author_facet Falcone, Colomba
Buzzi, Maria Paola
Bozzini, Sara
Boiocchi, Chiara
D'Angelo, Angela
Schirinzi, Sandra
Esposito, Ciro
Torreggiani, Massimo
Choi, Jasmine
Ochan Kilama, Michael
Mancia, Giuseppe
author_sort Falcone, Colomba
collection PubMed
description Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity.
format Online
Article
Text
id pubmed-3306936
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33069362012-04-03 Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT Falcone, Colomba Buzzi, Maria Paola Bozzini, Sara Boiocchi, Chiara D'Angelo, Angela Schirinzi, Sandra Esposito, Ciro Torreggiani, Massimo Choi, Jasmine Ochan Kilama, Michael Mancia, Giuseppe Mediators Inflamm Research Article Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity. Hindawi Publishing Corporation 2012 2012-02-13 /pmc/articles/PMC3306936/ /pubmed/22474401 http://dx.doi.org/10.1155/2012/874149 Text en Copyright © 2012 Colomba Falcone et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Falcone, Colomba
Buzzi, Maria Paola
Bozzini, Sara
Boiocchi, Chiara
D'Angelo, Angela
Schirinzi, Sandra
Esposito, Ciro
Torreggiani, Massimo
Choi, Jasmine
Ochan Kilama, Michael
Mancia, Giuseppe
Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
title Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
title_full Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
title_fullStr Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
title_full_unstemmed Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
title_short Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
title_sort microalbuminuria and srage in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of talent
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306936/
https://www.ncbi.nlm.nih.gov/pubmed/22474401
http://dx.doi.org/10.1155/2012/874149
work_keys_str_mv AT falconecolomba microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT buzzimariapaola microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT bozzinisara microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT boiocchichiara microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT dangeloangela microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT schirinzisandra microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT espositociro microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT torreggianimassimo microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT choijasmine microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT ochankilamamichael microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent
AT manciagiuseppe microalbuminuriaandsrageinhighriskhypertensivepatientstreatedwithnifedipinetelmisartancombinationtreatmentasubstudyoftalent